enGene Inc. (ENGN)
NASDAQ: ENGN
· Real-Time Price · USD
7.75
-0.39 (-4.79%)
At close: Oct 03, 2025, 3:59 PM
7.60
-1.94%
After-hours: Oct 03, 2025, 07:22 PM EDT
-4.79% (1D)
| Bid | 7.5 |
| Market Cap | 396.74M |
| Revenue (ttm) | 480K |
| Net Income (ttm) | -43.09M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -4.08 |
| Forward PE | -3.42 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.83 |
| Volume | 80,019 |
| Avg. Volume (20D) | 173,868 |
| Open | 8.28 |
| Previous Close | 8.14 |
| Day's Range | 7.51 - 8.28 |
| 52-Week Range | 2.65 - 11.00 |
| Beta | -0.26 |
| Ex-Dividend Date | n/a |
About ENGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+1.19%
EnGene Holdings shares are trading higher after Pi...
Unlock content with
Pro Subscription
11 months ago
+1.91%
EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.
2 months ago · businesswire.com
enGene Announces Board and Leadership Appointments to Support Commercial ReadinessBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of t...